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The correlation between colorectal cancer rates of proliferation
and apoptosis and systemic cytokine levels; plus their influence
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Colorectal cancer development is associated with a shift in host immunity with suppression of the cell-mediated immune system
(CMI) and a predominance of humoral immunity (HI). Tumour progression is also associated with increased rates of cell proliferation
and apoptosis. The aim of this study was to investigate whether these factors correlate and have an influence upon prognosis. Long-
term follow-up was performed on 40 patients with colorectal cancer who had levels of tumour necrosis factor (TNF)-a, interferon
(IFN)-g and interleukin (IL)-10 measured from stimulated blood cultures before surgery. Their archived tumour specimens were
analysed to determine a Ki-67-derived proliferation index (PI) and a M30-derived apoptosis index (AI). Tumour necrosis factor-a
levels negatively correlated to tumour proliferation (r¼0.697, P¼ 0.01). Interleukin-10 levels had a positive correlation with
tumour proliferation (r¼ 0.452, P¼ 0.05) and apoptosis (r¼ 0.587, P¼ 0.01). Patient survival correlates to tumour pathological
stage (P¼ 0.0038) and vascular invasion (P¼ 0.0014). An AIp0.6% and TNF-a levelsX8148 pg ml1 correlate to improved survival
(P¼ 0.032, P¼ 0.021). Tumour proliferation and apoptosis correlate to progressive suppression of the CMI-associated cytokine TNF-
a and to and higher levels of IL-10. Survival is dependent upon the histological stage of the tumour, vascular invasion, rates of
apoptosis and proliferation and systemic immunity which are all interconnected.
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The basis for the development of colorectal cancer is believed to be
the adenoma-carcinoma sequence (Weitz et al, 2005), which
involves a stepwise progression from normal to dysplastic
epithelium to carcinoma. It is associated with the accumulation
of multiple, clonally selected genetic alterations (Leslie et al, 2002)
and results in disturbed rates of cell proliferation and apoptosis
(Aotake et al, 1999).
Cell proliferation and apoptosis are dependent upon the
pathways that govern the different cell cycle phases. These
pathways are under genetic control but are influenced by both
exogenous and endogenous stimuli (Funk, 1999). The immune
system and its components are key regulators of cell proliferation
and cell death when there are inflammatory responses, for
example, during wound healing (Robinson and Coussens, 2005).
The majority of colorectal cancer evolves in a chronic inflamma-
tory background (Higaki et al, 1999) and there is strong evidence
of an immune response to colorectal cancer (Naito et al, 1998;
Garrido and Algarra, 2001; Nagorsen et al, 2005).
In order for tumours to establish and progress it is thought that
suppression of the host’s immune system is needed (Berghella
et al, 1996). Tumour-induced immune suppression occurs at both
a molecular and cellular level and progresses to affect the whole
organism (Zou, 2005). Colorectal cancer results in a fundamental
shift in immunity with suppression of the cell-mediated immune
system (CMI), associated with tumour rejection (Kidd, 2003), and
a predominance of humoral immunity (HI) which conversely
prevents rejection (Terabe et al, 2004). There is a reduced
production of cytokines from the CMI-associated Th1 lymphocytes
while those produced by the Th2 lymphocytes (associated with HI)
appear to remain at normal or even elevated levels. The further the
disease has progressed the more significant these imbalances
become and complete resection of the tumour reverses these
changes (O’Hara et al, 1998; Heriot et al, 2000; Galizia et al, 2002;
Shibata et al, 2002).
The purpose of this study was to correlate colorectal tumour
rates of proliferation and apoptosis with host systemic cytokine
levels and investigate what influence these factors have upon
patient prognosis. Archived cancer specimens from a group of
patients, who were previously studied to investigate the relation-
ship between systemic cytokine levels and colorectal cancer
(Heriot et al, 2000), were stained with the antibody Ki67 to
measure proliferation and the antibody M30 to measure apoptosis.
Long-term patient follow-up was also preformed. The original
work had shown a suppression of CMI-associated cytokines,
tumour necrosis factor-a (TNF-a) and interferon-g (IFN-g) in
patients with colorectal cancer that was greater in those with a
Dukes’ C tumour compared to those with either a Dukes’ A or B
tumour and was reversed by surgery. No difference had been
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found in the levels of the HI-associated cytokine interleukin-10
(IL-10) in patients with colorectal tumours compared to the
controls both pre- and postsurgery (Heriot et al, 2000).
PATIENTS AND METHODS
Between March 1997 and March 1998, 53 patients (34 male
patients) diagnosed at one institution with primary colorectal
cancer were recruited. All patients gave written, informed consent
to the study. Ethical approval for the study was obtained from the
local ethical committee.
All patients had adenocarcinoma of the colon and rectum.
Before treatment a single heparinised venous blood sample was
taken from each patient for analysis. Following surgery a further
venous samples was taken a minimum of 4 weeks postsurgery to
be used for postoperative data analysis. The blood was diluted
with RPMI-1640 medium (1 : 4) þ glutamine (2 mM) and then
stimulated for 24 h with lipopolysaccharide. Cell-free supernatants
were then assayed for TNF-a, IFN-g and IL-10 by enzyme-linked
immunosorbent assay (ELISA) using an assay procedure and
reagents (anticytokine capture monoclonal antibody, biotinylated
anticytokine detecting antibody and recombinant cytokine)
provided by Pharmingen (Cambridge Bioscience, UK) (Heriot
et al, 2000).
Clinical follow-up was performed every 3 months for the first 2
years after treatment, 6 monthly during the third year and annually
thereafter till the age of 80 years. In December 2004 patients with
preoperative cytokine levels were followed up and their archived
pathological specimens were reviewed retrospectively. Patient’s
who had chemotherapy and/or radiotherapy before surgery,
patients with synchronous, or metachronous tumours, inflamma-
tory conditions or any immunosuppressive condition including
immunosuppressive medications were excluded. The interval from
the date of resection to the date of death or last contact (if alive)
was used for survival analysis with a minimum length of follow-up
set at 5 years. The end points of the follow-up study were; cancer-
related survival and the development of local recurrence or distant
metastases.
Immunohistochemistry
Sections (3 ı`m thick) were cut from paraffin blocks on to
SuperFrosts Plus slides (Menzel-Glaser, Germany), dried over-
night at 601C, dewaxed and taken down to water. Endogenous
peroxidase activity was blocked by placing slides in 500 ml of a
10% hydrogen peroxidase solution for 8 min. Slides were washed
in tap water and heated for 8 min in 1000 ml of Tris-EDTA-citrate
buffer, pH 7.8 (preheated for 24 min) in a microwaveable pressure
cooker if for Ki67 staining and for 35 min in 1000 ml of Tris-EDTA
pH 9.9 in an unpressurised container if for M30 staining. After
repeat washing, the slides were ringed with a hydrophobic
ImmEdget pen (Vector Laboratories Inc., Bulingame, CA 94010,
USA) and rinsed in Optimax Wash Buffers (Biogenex Labora-
tories, San Ramon, CA, USA). The primary antibodies NCL-Ki67p
(Novocastra Laboratories Ltd, Newcastle upon Tyne, England, UK)
and M30 CytoDEATH (Roche Applied Science, Lewes, England,
UK) were applied to the sections according to the Optimax stainer
programme having been diluted to 1 : 6000 and 1 : 50, respectively,
with ChemMatet Antibody Diluent (DakoCytomation). The
stainer was programmed using Optimaxt Software Version 2.7
to the following specifications: (1) incubation in primary antibody,
30 and 45 min, respectively, (2) 30 or 45 min, respectively, in
polymetric conjugate, (3) 10 min in working substrate solution;
rinsing between all stages with Optimax wash buffers. Slides
stained with M30 had the working substrate solution (ChemMatet
Envisiont Detection kit, Peroxidase/DAB, Rabbit/mouse (Dako-
Cytomation) applied 45 min after the polymetric conjugate. On
completion of the staining, the slides were washed in tap water,
and counterstained with Mayer’s haematoxylin for 1 min and then
differentiated briefly in 1% acid alcohol, blued in running tap
water, dehydrated cleared and mounted.
Evaluation of staining results
All specimens were examined by an independent investigator with
no knowledge of the clinical or pathological data. Counts were
made randomly from each slide with at least 1000 epithelial cells
counted in all cases. Ki67 positivity and M30 positivity were
identified and positive cells were expressed as a percentage of the
total number of cells counted (proliferation index (PI) and
apoptotic index (AI)) (Figures 1 and 2).
Statistical analysis
Results are noted as mean þ / standard deviation (s.d.).
Correlations between proliferation and apoptotic activity and
systemic cytokine levels were assessed using the Spearman test.
Independent t-tests were used to analyse means. In order to
perform survival analysis and create probability curves dependent
upon tumour rates of proliferation and apoptosis as well as
systemic cytokine levels the Kaplan–Meier method was used. A
log-rank test was used to compare the probability curves. Hazard
ratios and 95% confidence intervals (CI) for cytokine values, PI,
AI, Dukes’ stage, differentiation and vascular invasion were
calculated for each factor in a Cox proportional hazards model.
In all cases, a P-value of o 0.05 indicated a significant difference.
All data were analysed using SPSSs Version 12.0 (SPSS Inc.,
Chicago, IL, USA).
RESULTS
Patient characteristics
From the original 53 patients, 40 (26 male patients) were eligible
for the study. Of them, 11 were excluded for having no
Figure 1 Histological section stained with anit-Ki67, 1 : 6000. Pretreat-
ment Tris-EDTA pH7.6 (magnification  200).
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preoperative cytokine values successfully measured, one for the
tumour being a local recurrence and one for being lost to follow-
up. Median age was 76.5 years old with a mean (s.d.) of 74.55
(11.80). In all, 35 were Caucasian, four were Asian and one was
Afro Caribbean. From this group of 40 patients, it was possible to
retrieve and successfully stain 31 histological specimens for
proliferation and apoptosis.
In December 2004, the median follow-up was 89 months (mean
(s.d.) 87.64 (4.02) months). Of the patients, four had Dukes’ A
tumours, 16 Dukes’ B tumours and the remaining 20 had Dukes’ C
tumours. In all, 24 patients were documented to have well or
moderately differentiated tumours while 15 had poorly differ-
entiated tumours. Vascular invasion was found in 14 patient’s
specimens. Overall mortality was 65% (26 patients) with a cancer-
related mortality of 50% (20 patients). Median survival was 21.5
months with a mean (s.d.) of 35.88 (33.64) months. Six patients at
the time of surgery had metastases with an additional five
developing metastases during follow-up. Five patients developed
local recurrence postsurgery. Cancer-related 5-year mortality in
this cohort of patients is noted to be high but was comparable to
national statistics (Cancer Stats: Large Bowel-UK, Cancer Research
UK, 2005) given the small number of patients involved.
Proliferative and apoptosis activity
The mean (s.d.) PI in the colorectal carcinomas was 52.39 (19.50)
%. The mean (s.d.) AI was 0.74 (0.6) %. Proliferative index and AI
did not correlate to Dukes’ histological stage but, as a combined
group, those patients who developed either local recurrence or
metastases had a significantly raised PI (P¼ 0.002) and AI
(P¼ 0.037). There was a strong positive correlation between AI
and PI (r¼ 0.675, P¼ 0.01).
Correlation between systemic cytokine levels and tumour
rates of proliferation and apoptosis
A significant negative correlation was found between systemic
TNF-a levels and tumour cell proliferation (r¼0.697, P¼ 0.01)
(Figure 3). A trend to negative correlation was seen when TNF-a
levels were correlated to apoptosis (r¼0.33) and IFN-g levels to
proliferation (r¼0.265). Patient systemic IL-10 levels had a
positive correlation with both tumour cell proliferation (r¼ 0.452,
P¼ 0.05) and apoptosis (r¼ 0.587, P¼ 0.01) (Figure 4(i) and (ii)).
Correlations to long-term prognosis
It was shown that the tumour’s pathological staging was of
significance when assessing which factors influenced survival. In
keeping with the expected survival distribution of patients with
colorectal cancer, those with Dukes’ C tumours had a poorer
survival compared to those with either a Dukes’ A or B tumour
(P¼ 0.0038). Vascular invasion was also correlated to reduced
survival (P¼ 0.0014) (Figure 5(i) and (ii)).
Tumour rates of proliferation and apoptosis Patients who had an
AI less than or equal to the median value of 0.6% (n¼ 16) had
significantly better overall survival than those whose value was
greater (n¼ 15) (log-rank P¼ 0.032) (Figure 6(i)). Patients who
had a PI less than or equal to the median value of 52.7% (n¼ 16)
showed a strong trend to improved survival (log-rank P¼ 0.051)
(Figure 6(ii)).
Systemic cytokine levels Using independent t-tests preoperative
cytokine levels were compared to see what correlation they had
with long-term survival, development of metastases and local
recurrence. Patients with a survival of greater than 1 year had
significantly higher levels of preoperative TNF-a than those that
did not (P¼ 0.005). There was no correlation between preoperative
IFN-g and IL-10 levels and 1-year survival. Preoperative cytokine
levels were not significantly different in those who developed
metastases or local recurrence compared to those who did not and
there were no statistically significant correlations with post-
operative cytokine levels.
In order to perform survival analysis patients were classified in
to two groups according to their cytokine values. When assessing
the influence of TNF-a patients were grouped as either having
values pthe median value of 8148 pg ml1 (n¼ 17) or
48148 pg ml1 (n¼ 18). To assess IL-10 patients were split
depending whether their values were 4 or pthe median value
of 0.4255 OD450 (n¼ 17 and n¼ 16, respectively). However, to
assess IFN-g patients were split in to those with values detectable
Figure 2 Histological section of colon stained with M30CytoDEATH 1:
50 TE buffer in the Decloaker (magnification  200).
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Figure 3 Correlation between preoperative TNF-a levels (pg ml1) and
tumour PI.
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(44.97 pg ml1) (n¼ 12) or not detectable (p4.7 pg ml1) (n¼ 26)
owing to a skewed patient distribution. Patients with TNF-a levels
48148 pg ml1 had significantly better survival than those with
TNF-a p8148 pg ml1 (P¼ 0.021) (Figure 7(i)). Patients with
detectable IFN-g levels showed a trend to improved survival
compared to those with undetectable levels, however, not reaching
significance (P¼ 0.148) (Figure 7(ii)). There was no statistical
difference between the two IL-10 groups although at 60 months it
is noted that cumulative survival is more than double in the group
with values p0.4255 OD450 (0.41 vs 0.18) (Figure 7(iii)).
Multivariate analysis performed to assess the significance of
independent factors upon 5-year survival demonstrated tumour
differentiation, AI and detectable IFN-g levels to be of statistical
significance (Table 1).
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Figure 4 (i) Correlation between preoperative IL-10 levels (OD450) and
tumour PI. (ii) Correlation between preoperative IL-10 levels (OD450) and
tumour AI.
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DISCUSSION
Colorectal carcinomas arise through a series of histological
changes, each of which is accompanied by specific genetic
alterations in a handful of oncogenes and tumour-suppressor
genes (Fodde et al, 2001). Chronic inflammation plays a causative
role in the molecular pathways of colon carcinogenesis (Itzkowitz
and Yio, 2004) and leads to altered rates of cell proliferation and
apoptosis, altered cellular adhesion, increased angiogenesis and
cellular transformation (Macarthur et al, 2004). Significantly,
chronic inflammation also causes negative feedback inhibition of
the CMI and causes a predominance of HI. This state of host
immunity is described in a number of malignant diseases and
inhibits immune-mediated tumour rejection (O’Byrne and Dalgleish,
2001).
Colorectal cancer has been shown to cause CMI suppression and
HI promotion that is linked to disease progression and has
an influence on survival. Decreased total numbers of the CMI
promoting Th1 CD4þ cells have been found in patients with
colorectal tumours (Nakayama et al, 2000). Lowered levels of CMI-
associated cytokines have been measured, corresponding to the
pathological stage of the tumour and reversed by surgery (O’Hara
et al, 1998; Heriot et al, 2000; Galizia et al, 2002; Shibata et al,
2002). It has also been demonstrated that elevated basal levels
of the HI-associated cytokine, IL-10, are correlated to reduced
disease-free survival (Galizia et al, 2002). The mechanisms through
which this shift in immunity is performed have not been fully
explained but include COX-2 overexpression (O’Byrne and
Dalgleish, 2001), histamine production (Tomita and Okabe,
2005) and increased expression of IL-10 (Ding et al, 2003).
There is evidence of an immune response to colorectal cancer
which can be correlated to improved survival (Naito et al, 1998);
however, many of the cell types active in chronic inflammation can
be found in the surrounding stroma and the neoplasm itself. This
includes a diverse leucocyte infiltrate of macrophages, neutrophils,
eosinophils and mast cells (Macarthur et al, 2004). Thus, the
secretion of extracellular proteases, proangiogenic factors, and
cytokines in the tumour microenvironment results in a chronic
inflammatory-like state in which CMI suppression takes place and
the control mechanisms for cell proliferation and apoptosis are
disturbed.
Despite there being only a small number of patients involved in
this study, it is the consistency in its results, relating rates of
proliferation and apoptosis to systemic cytokine levels and the
trends seen when looking at long-term survival, that suggest
progressive changes to host immunity with colorectal cancer
advancement. Tumour rates of proliferation and apoptosis have a
negative correlation with the CMI-associated cytokines TNF-a and
IFN-g while having a positive one with IL-10 (HI associated).
Elevated AI and PI were linked with reduced long-term survival
and the development of metastases and/or local recurrence.
Correspondingly, reduced rates of survival are seen with lowered
levels of TNF-a. It is not possible to comment from these data
whether a specific cytokine level or tumour proliferation or
apoptosis rate has a prognostic value and it should be noted that a
larger range of cytokines and T-cell responses would need to be
measured to make a full evaluation of any shift in host immunity
from CMI to HI. However, it can be concluded that there is an
impact upon patient survival through the systemic suppression of
the CMI-associated cytokines TNF-a and IFN-g and promotion of
the HI-associated IL-10.
The balance between cell proliferation and cell loss through
apoptosis determines how fast a tumour grows and is an important
determinant of tumour behaviour (Koornstra et al, 2003). There
are conflicting reports regarding the implications of proliferation
and apoptosis rates upon patient prognosis (Koornstra et al, 2003;
Salminen et al, 2005; Valera et al, 2005), however, it is generally
accepted that as tumours advance proliferative activity increases
and higher rates of apoptosis are seen (Koornstra et al, 2004). This
study’s results conform to these findings demonstrating increased
rates of proliferation and apoptosis in the group of patients
developing either metastatic disease or local recurrence with a
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Figure 6 (i) AI survival functions. (ii) PI survival functions.
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Table 1 Multivariate analysis of significant factors associated with overall 5-year survival in colorectal cancer
Regression coefficient s.e. Hazard ratio P*
Dukes’ stage (A/B) vs (C) 0.687 1.23 1.99 (0.18, 22.00) 0.576
Differentiation (well/mod) vs (poor) 2.065 0.88 0.127 (0.23, 0.71) 0.019
Vascular invasion
(+ve vs ve) -2.903 1.62 0.055 (0.01, 1.32) 0.074
Proliferation index (continuous variable) -0.021 0.04 0.98 (0.91, 1.06) 0.609
Apoptosis index (continuous index) 6.691 3.05 805.12 (2.02, 320256.16) 0.028
TNF-a (48148 pg ml1 vs p8148 pg ml1) -0.983 1.42 0.374 (0.023, 6.05) 0.489
IFN-g (410 pg ml1 vs p10 pg ml1) 5.211 2.22 183.33 (2.35, 1433.71) 0.019
IL10 (4 0.4255 OD450 vs p0.4255 OD450) 1.640 1.47 5.153 (0.29, 91.24) 0.263
Values in parentheses are 95% CI. *Cox proportional hazards model.
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strong positive correlation between PI and AI also noted. The
demonstrated link between increased rates of apoptosis and
proliferation with reduced survival in this cohort of patients could
possibly be explained by this pathological-proliferation/apoptosis
correlation.
The relationship between cytokines and tumour development is
complex with both stimulation and inhibition exhibited by the
same one cytokine. Their action depends upon the cocktail of
other factors in the surrounding microenvironment, including
other cytokines, chemokines, growth and angiogenic factors as
well as its own actual concentration. For example, TNF-a can
induce apoptosis in tumour cells of the colon (Jacobson-Brown
and Neuman, 2004) and its cytotoxic effect is synergistically
enhanced by IFN-g in vitro and in vivo (Sveinbjornsson et al,
1997). However, when chronically produced TNF may act as an
endogenous tumour promoter, contributing to tissue remodelling
and stromal development necessary for tumour growth and spread
(Balkwill and Mantovani, 2001). Interleukin-10 is believed to
contribute to tumour development by suppressing the antitumour
immune responses (Matsuda et al, 1994). Gene therapy studies,
however, have demonstrated IL-10-mediated inhibition of tumour
growth and metastases with the outcome appearing dependent
upon host immune competency and levels of IL-10 expression
(Erdman et al, 2003).
Measuring systemic levels of three cytokines cannot accurately
represent the specific interactions occurring in the tumour
microenvironment or give a full representation of systemic
immunity. However, it does enable potential trends or changes
in host immune competence to be proposed. Thus, this study
suggests a potential shift in host immunity with CMI suppression
and HI promotion, which correlates to increasing tumour rates of
proliferation and apoptosis. The effect of any one single cytokine’s
is not implicated.
These results linking the host’s immune response to colorectal
cancer progression and prognosis highlight the need for im-
munotherapies, which enhance CMI. Manipulating the host’s
systemic immune response to a tumour may lead to an
environment in which tumour cell recognition is more successfully
induced (Shibata et al, 2002) and several studies have demon-
strated that CMI-associated cytokines enhance the therapeutic
efficacy of antitumour responses (Nakamori et al, 2003). Combin-
ing immunotherapies with other treatment modalities including
chemotherapy and radiotherapy may also lead to more successful
results.
CONCLUSION
There is a trend to TNF-a and IFN-g suppression with IL-10
promotion as colorectal cancer advances. Cytokine levels correlate
to increased tumour rates of proliferation and apoptosis.
Patient survival is influenced by the histological stage of the
tumour, vascular invasion, tumour rates of apoptosis and
proliferation and systemic immunity. All of these factors are
interconnected. Immunotherapies that can enhance cell-mediated
immunity may lead to prolonged survival and should be
considered in combination with other treatments used to induce
tumour recognition.
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